Evidence map›Paper›PMID 35471842›Full record

ArticleHuman vaccines & immunotherapeutics2022

Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine.

Chenyang Miao, Xinxing Ma, Jiang Fan, Li Shi, Jian Wei

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenyang MiaoDepartment of Formulation Development, Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.ORCID 0000-0002-7892-9608
Xinxing MaDepartment of Formulation Development, Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.ORCID 0000-0003-0562-1829
Jiang FanDepartment of Formulation Development, Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.
Li ShiDepartment of Formulation Development, Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.
Jian WeiDepartment of Formulation Development, Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.ORCID 0000-0001-9314-2080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human papillomavirus (HPV) vaccine is the simplest, most economical, convenient, and effective method of preventing cervical cancer. However, the current HPV vaccine is supplied as a single-dose vial with a relatively high cost per dose, which hinders its supply to low- and middle-income countries (LMICs), where the demand for HPV vaccine is highest. Therefore, it is necessary to develop a multi-dose HPV vaccine to promote large-scale affordable vaccination in LMICs. Moreover, the addition of preservatives is required to reduce the risk of microbial contamination in multi-dose vaccines within a single vial. In this study, we investigated the effects of six preservatives on HPV 16L1 and 18L1 virus-like particles in solution, as well as the aluminum adsorption status, under normal and high-temperature conditions. Multiple methods were employed, including dynamic light scattering, differential scanning calorimetry, an

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesParabensAlphapapillomavirusAnimalsCost-Benefit AnalysisFemaleHumansMicePreservatives, PharmaceuticalUterine Cervical NeoplasmsVaccinationmethylparabenPapillomavirus VaccinesParabensPreservatives, Pharmaceuticalaluminum adsorptionantimicrobial effectivenessmethylparabenMulti-dose HPV-2 vaccinepreservativestability

Identifiers

PMID35471842
PMCPMC9302532
OpenAlexW4224998866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.